Claims for Patent: 5,859,311

Summary for Patent: 5,859,311

Title:	Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
Abstract:	Transgenic mice express increased levels of neurotrophin-3 (NT-3) in epithelium when their ancestors are microinjected with the NT-3 gene. The NT-3 growth factor expressing transgenic mice are useful in the study of neurodegenerative disorders of the brain such as Parkinson\'s syndrome and Alzheimer\'s disease, of the spinal cord motor neurons such as amyotrophic lateral sclerosis, and for testing drug candidates for the treatment of these diseases.
Inventor(s):	Albers; Kathryn M. (Lexington, KY), Davis; Brian M. (Lexington, KY)
Assignee:	University of Kentucky Research Foundation (Lexington, KY)
Application Number:	08/534,685
Patent Claims:	1. A transgenic mouse whose somatic and germ cells contain and express an NT-3 transgene encoding mouse neurotrophic growth factor 3 (NT-3), wherein as a result of said expression, the peripheral nervous system of said mouse exhibits the following characteristics: (a) NT-3 responsive neurons that are rescued from programmed cell death that normally occurs during the development of said mouse; (b) an increase in sensory neurons that express trk C receptor relative to a mouse that does not express said NT-3 transgene; and (c) larger Merkel cell sensory units in the skin of said mouse than in the skin of a mouse that does not express said NT-3 transgene; and further wherein said NT-3 transgene comprises a mouse NT-3 gene operatively linked at its 5' end to a human K14 keratin promoter and enhancer region and operatively linked at its 3' end to a contiguous 1.8 kbp region of the human growth hormone gene, said region comprising (1) an intron of the human growth hormone gene, and (2) a polyadenylation signal sequence. 2. The mouse of claim 1, wherein said mouse is fertile and capable of transmitting said NT-3 gene to its offspring. 3. The mouse of claim 1, wherein said NT-3 gene has been introduced into an ancestor of said mouse at an embryonic stage by microinjection. 4. The mouse of claim 1, wherein said human K14 keratin promoter and enhancer region is a 2.1 kbp sequence 5' upstream from the human K14 keratin gene. 5. The mouse of claim 1, wherein said NT-3 transgene is contained in a plasmid having American Type Culture Collection Accession No. 69889. 6. A method of testing the effect of a drug on the mouse of claim 1, comprising administering said drug to said mouse, and thereafter determining any behavioral effects and tissue changes in said mouse. 7. The method of claim 6, wherein said drug is a candidate for treatment of a neurodegenerative disorder.

Details for Patent 5,859,311

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26